Literature DB >> 24293347

Genetics and personalized medicine--a role in statin therapy?

Jaideep Patel1, Thura Abd, Roger S Blumenthal, Khurram Nasir, H Robert Superko.   

Abstract

Pharmacogenetics uses the genetic variation in metabolic pathways to identify groups of patients who may respond differently in terms of therapeutic and adverse effects. Much clinical interest lies in drug metabolism and the opportunity to improve prescribing efficacy and safety. Owing to widespread use and increasing concern regarding side effects, statins are of significant interest in this area. Among other benefits, statins have been shown to improve lipid profiles and reduce coronary heart disease event rates in many populations. However, variability in drug response exists, and genetic variability may be a contributing factor. Our primary goal is to feature the most important genes involved in lipid metabolism, clinical outcomes, and statin-induced side effects, highlighting genome-wide association studies and the candidate gene approach.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24293347     DOI: 10.1007/s11883-013-0384-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  83 in total

Review 1.  Safety of statins: focus on clinical pharmacokinetics and drug interactions.

Authors:  Stefano Bellosta; Rodolfo Paoletti; Alberto Corsini
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

2.  High-density lipoprotein and cardiovascular risk.

Authors:  Peter P Toth
Journal:  Circulation       Date:  2004-04-20       Impact factor: 29.690

3.  Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

Authors:  L R Brunham; P J Lansberg; L Zhang; F Miao; C Carter; G K Hovingh; H Visscher; J W Jukema; A F Stalenhoef; C J D Ross; B C Carleton; J J P Kastelein; M R Hayden
Journal:  Pharmacogenomics J       Date:  2011-01-18       Impact factor: 3.550

4.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

Authors:  Mikko Niemi; Marja K Pasanen; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2006-10       Impact factor: 6.875

5.  The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype.

Authors:  Anke-Hilse Maitland-van der Zee; Bruno H Stricker; Olaf H Klungel; John J Kastelein; Albert Hofman; Jacqueline C Witteman; Monique M Breteler; Hubertus G Leufkens; Cornelia M van Duijn; Anthonius de Boer
Journal:  Pharmacogenetics       Date:  2002-11

6.  No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.

Authors:  Jemma C Hopewell; Sarah Parish; Robert Clarke; Jane Armitage; Louise Bowman; Jorg Hager; Mark Lathrop; Rory Collins
Journal:  J Am Coll Cardiol       Date:  2011-03-31       Impact factor: 24.094

7.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

Authors:  Deepak Voora; Svati H Shah; Ivan Spasojevic; Shazia Ali; Carol R Reed; Benjamin A Salisbury; Geoffrey S Ginsburg
Journal:  J Am Coll Cardiol       Date:  2009-10-20       Impact factor: 24.094

8.  Effects of polymorphisms in apolipoproteins E, A-IV, and H on quantitative traits related to risk for cardiovascular disease.

Authors:  J Kaprio; R E Ferrell; B A Kottke; M I Kamboh; C F Sing
Journal:  Arterioscler Thromb       Date:  1991 Sep-Oct

9.  Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.

Authors:  David L McClure; Robert J Valuck; Morton Glanz; James R Murphy; John E Hokanson
Journal:  J Clin Epidemiol       Date:  2007-03-26       Impact factor: 6.437

10.  Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation study.

Authors:  Patrick Linsel-Nitschke; Anika Götz; Jeanette Erdmann; Ingrid Braenne; Peter Braund; Christian Hengstenberg; Klaus Stark; Marcus Fischer; Stefan Schreiber; Nour Eddine El Mokhtari; Arne Schaefer; Jürgen Schrezenmeir; Jürgen Schrezenmeier; Diana Rubin; Anke Hinney; Thomas Reinehr; Christian Roth; Jan Ortlepp; Peter Hanrath; Alistair S Hall; Massimo Mangino; Wolfgang Lieb; Claudia Lamina; Iris M Heid; Angela Doering; Christian Gieger; Annette Peters; Thomas Meitinger; H-Erich Wichmann; Inke R König; Andreas Ziegler; Florian Kronenberg; Nilesh J Samani; Heribert Schunkert
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  4 in total

1.  Serum Plant Sterols Associate with Gallstone Disease Independent of Weight Loss and Non-Alcoholic Fatty Liver Disease.

Authors:  Pirjo Käkelä; Ville Männistö; Imre Ilves; Maija Vaittinen; Milla-Maria Tauriainen; Matti Eskelinen; Helena Gylling; Hannu Paajanen; Jussi Pihlajamäki
Journal:  Obes Surg       Date:  2017-05       Impact factor: 4.129

2.  Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.

Authors:  Htet Khine; Wei Cheng Yuet; Beverley Adams-Huet; Zahid Ahmad
Journal:  Am Heart J       Date:  2016-06-09       Impact factor: 4.749

Review 3.  Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis.

Authors:  Jiajia Jiang; Qing Tang; Jing Feng; Rong Dai; Yang Wang; Yuan Yang; Xiaojun Tang; Changkai Deng; Huan Zeng; Yong Zhao; Fan Zhang
Journal:  Springerplus       Date:  2016-08-19

4.  Effect of statin use on outcome of symptomatic cholelithiasis: a case-control study.

Authors:  Jukka Pulkkinen; Matti Eskelinen; Vesa Kiviniemi; Tuukka Kotilainen; Markus Pöyhönen; Lasse Kilpeläinen; Pirjo Käkelä; Helena Kastarinen; Hannu Paajanen
Journal:  BMC Gastroenterol       Date:  2014-07-03       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.